BACKGROUND: The Social Security Administration (SSA) is considering whether schizophrenia may warrant inclusion in their new "Compassionate Allowances" process, which aims to identify diseases and other medical conditions that invariably quality for Social Security disability benefits and require no more than minimal objective medical information. This paper summarizes evidence on the empirical association between schizophrenia and vocational disability. A companion paper examines the reliability and validity of schizophrenia diagnosis which is critically relevant for granting a long-term disability on the basis of current diagnosis. METHODS: This is a selective literature review and synthesis, based on a work plan developed in a meeting of experts convened by the National Institute of Mental Health and the SSA. This review of the prevalence of disability is focused on the criteria for receipt of disability compensation for psychotic disorders currently employed by the SSA. RESULTS: Disability in multiple functional domains is detected in nearly every person with schizophrenia. Clinical remission is much more common than functional recovery, but most patients experience occasional relapses even with treatment adherence, and remissions do not predict functional recovery. Under SSA's current disability determination process, approximately 80% of SSDI/SSI applications in SSA's diagnostic category of "Schizophrenia/Paranoid Functional Disorders" are allowed, compared to around half of SSDI/SSI applications overall. Moreover, the allowance rate is even higher among applicants with schizophrenia. Many unsuccessful applicants are not denied, but rather simply are unable to manage the process of appeal after initial denials. DISCUSSION: Research evidence suggests that disability applicants with a valid diagnosis of schizophrenia have significant impairment across multiple dimensions of functioning, and will typically remain impaired for the duration of normal working ages or until new interventions are developed.
BACKGROUND: The Social Security Administration (SSA) is considering whether schizophrenia may warrant inclusion in their new "Compassionate Allowances" process, which aims to identify diseases and other medical conditions that invariably quality for Social Security disability benefits and require no more than minimal objective medical information. This paper summarizes evidence on the empirical association between schizophrenia and vocational disability. A companion paper examines the reliability and validity of schizophrenia diagnosis which is critically relevant for granting a long-term disability on the basis of current diagnosis. METHODS: This is a selective literature review and synthesis, based on a work plan developed in a meeting of experts convened by the National Institute of Mental Health and the SSA. This review of the prevalence of disability is focused on the criteria for receipt of disability compensation for psychotic disorders currently employed by the SSA. RESULTS: Disability in multiple functional domains is detected in nearly every person with schizophrenia. Clinical remission is much more common than functional recovery, but most patients experience occasional relapses even with treatment adherence, and remissions do not predict functional recovery. Under SSA's current disability determination process, approximately 80% of SSDI/SSI applications in SSA's diagnostic category of "Schizophrenia/Paranoid Functional Disorders" are allowed, compared to around half of SSDI/SSI applications overall. Moreover, the allowance rate is even higher among applicants with schizophrenia. Many unsuccessful applicants are not denied, but rather simply are unable to manage the process of appeal after initial denials. DISCUSSION: Research evidence suggests that disability applicants with a valid diagnosis of schizophrenia have significant impairment across multiple dimensions of functioning, and will typically remain impaired for the duration of normal working ages or until new interventions are developed.
Authors: P D Harvey; P J Moriarty; J I Friedman; L White; M Parrella; R C Mohs; K L Davis Journal: Biol Psychiatry Date: 2000-06-01 Impact factor: 13.382
Authors: J A Lieberman; J M Alvir; A Koreen; S Geisler; M Chakos; B Sheitman; M Woerner Journal: Neuropsychopharmacology Date: 1996-03 Impact factor: 7.853
Authors: Marc De Hert; Ruud van Winkel; Martien Wampers; John Kane; Jim van Os; Joseph Peuskens Journal: Schizophr Res Date: 2007-03-02 Impact factor: 4.939
Authors: Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet Journal: Schizophr Bull Date: 2008-05-20 Impact factor: 9.306
Authors: Ricardo E Carrión; Barbara A Cornblatt; Danielle McLaughlin; Jeremy Chang; Andrea M Auther; Ruth H Olsen; Daniel C Javitt Journal: Schizophr Res Date: 2015-02-23 Impact factor: 4.939
Authors: Danielle McLaughlin; Ricardo E Carrión; Andrea M Auther; Doreen M Olvet; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Robert K Heinssen; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Terry E Goldberg; Philip D Harvey; Barbara A Cornblatt Journal: Schizophr Bull Date: 2016-04-22 Impact factor: 9.306
Authors: David Kimhy; Julia Vakhrusheva; Samira Khan; Rachel W Chang; Marie C Hansen; Jacob S Ballon; Dolores Malaspina; James J Gross Journal: J Psychiatr Res Date: 2014-02-11 Impact factor: 4.791
Authors: Gabriela Vargas; Martin Strassnig; Samir Sabbag; Felicia Gould; Dante Durand; Laura Stone; Thomas L Patterson; Philip D Harvey Journal: Schizophr Res Cogn Date: 2014-03
Authors: Susan H Busch; Ezra Golberstein; Howard H Goldman; Christine Loveridge; Robert E Drake; Ellen Meara Journal: Psychiatr Serv Date: 2019-09-04 Impact factor: 3.084
Authors: Tara Kingston; Paul J Scully; David J Browne; Patrizia A Baldwin; Anthony Kinsella; Eadbhard O'Callaghan; Vincent Russell; John L Waddington Journal: CNS Neurosci Ther Date: 2018-03-25 Impact factor: 5.243
Authors: Jamie Joseph; William S Kremen; Carol E Franz; Stephen J Glatt; Joyce van de Leemput; Sharon D Chandler; Ming T Tsuang; Elizabeth W Twamley Journal: Schizophr Res Date: 2017-01-28 Impact factor: 4.939
Authors: W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff Journal: Schizophr Bull Date: 2014-04 Impact factor: 9.306
Authors: Ricardo E Carrión; Andrea M Auther; Danielle McLaughlin; Ruth Olsen; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Barbara A Cornblatt Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306